1 week Ago By Defense World Staff
Norges Bank purchased a new stake in shares of Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO – Free Report ) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 145,092 shares of the biopharmaceutical company’s stock, valued at approximately $4,768,000.
Norges Bank owned about 0.25% of Agios Pharmaceuticals at the end of the most recent reporting period. A number of other hedge funds also recently modified their holdings of the stock.
FMR LLC increased its holdings in Agios Pharmaceuticals by 283.2% in the 3rd quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company’s stock valued at $2,017,000 after buying an additional 33,546 shares during the period.
BNP Paribas Financial Markets increased its holdings in Agios Pharmaceuticals by 15.1% in the third quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company’s stock valued at $531,000 after purchasing an additional 1,570 shares during the period.
Verition Fund Management LLC bought a new position in shares of Agios Pharmaceuticals during the third quarter worth about $315,000. State Street Corp lifted its position in shares of Agios Pharmaceuticals by 10.2% in the 3rd quarter.
State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after purchasing an additional 216,484 shares during the period. Finally, XTX Topco Ltd lifted its holdings in Agios Pharmaceuticals by 56.2% in the third quarter.
XTX Topco Ltd now owns 8,329 shares of the biopharmaceutical company’s stock valued at $370,000 after buying an additional 2,996 shares during the period. Analyst Upgrades and Downgrades A number of analysts recently commented on AGIO shares. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research report on Monday, February 24th.
They issued a “buy” rating and a $58.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th.
Finally, StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company.
According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $56.57. Agios Pharmaceuticals Stock Performance AGIO opened at $26.
28 on Thursday. Agios Pharmaceuticals, Inc. has a 52-week low of $23.
42 and a 52-week high of $62.58. The company’s 50-day simple moving average is $31.
70 and its two-hundred day simple moving average is $39.55. The stock has a market capitalization of $1.
51 billion, a P/E ratio of 2.32 and a beta of 0.83.
Agios Pharmaceuticals ( NASDAQ:AGIO – Get Free Report ) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.
69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.
51% and a net margin of 1,845.92%. Research analysts forecast that Agios Pharmaceuticals, Inc.
will post -6.85 EPS for the current fiscal year. Agios Pharmaceuticals Company Profile ( Free Report ) Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. Featured Articles Five stocks we like better than Agios Pharmaceuticals The How And Why of Investing in Oil Stocks Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore What is the Shanghai Stock Exchange Composite Index? Are Tariffs Threatening Disney’s Comeback Story? 3 Fintech Stocks With Good 2021 Prospects Is Alphabet a Generational Buying Opportunity at These Levels? Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
